Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

R. S. Bhatt; A. J. Zurita; A. O'Neill; A. Norden-Zfoni; L. Zhang; H. K. Wu; P. Y. Wen; D. George; V. P. Sukhatme; M. B. Atkins; J. V. Heymach

doi:10.1038/bjc.2011.186

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

R. S. Bhatt, A. J. Zurita, A. O'Neill, A. Norden-Zfoni, L. Zhang, H. K. Wu, P. Y. Wen, D. George, V. P. Sukhatme, M. B. Atkins, J. V. Heymach

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Background:Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC.Methods:We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial progenitors (CEPs).Results:In patients with VHL disease and RCC and those with sporadic RCC (N10), CEPs and the CEP:mCEC ratio were higher than in normal subjects (N17) (median CEPs: 0.97 vs 0.19 cells l 1, respectively, P0.01; median CEP:mCEC: 0.92 vs 0.58, respectively, P0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy RCC patient samples (N20), CEPs decreased after surgery (median difference 0.02 cells l 1, 0.06 to 1.2; P0.05).Conclusion: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL.

Original language	English (US)
Pages (from-to)	112-117
Number of pages	6
Journal	British journal of cancer
Volume	105
Issue number	1
DOIs	https://doi.org/10.1038/bjc.2011.186
State	Published - Jun 28 2011

Keywords

angiogenesis
biomarker
circulating endothelial cells
renal cancer
von Hippel-Lindau (VHL) disease

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2011.186

Cite this

@article{d1ab180b7d3647d4a95b3b7e3210af2c,

title = "Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma",

abstract = "Background:Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC.Methods:We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial progenitors (CEPs).Results:In patients with VHL disease and RCC and those with sporadic RCC (N10), CEPs and the CEP:mCEC ratio were higher than in normal subjects (N17) (median CEPs: 0.97 vs 0.19 cells l 1, respectively, P0.01; median CEP:mCEC: 0.92 vs 0.58, respectively, P0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy RCC patient samples (N20), CEPs decreased after surgery (median difference 0.02 cells l 1, 0.06 to 1.2; P0.05).Conclusion: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL.",

keywords = "angiogenesis, biomarker, circulating endothelial cells, renal cancer, von Hippel-Lindau (VHL) disease",

author = "Bhatt, {R. S.} and Zurita, {A. J.} and A. O'Neill and A. Norden-Zfoni and L. Zhang and Wu, {H. K.} and Wen, {P. Y.} and D. George and Sukhatme, {V. P.} and Atkins, {M. B.} and Heymach, {J. V.}",

note = "Funding Information: This work was supported in part by the Clinical Investigator Training Program, Beth Israel Deaconess Medical Center – Harvard/MIT Health Sciences and Technology (to RSB); by the AstraZeneca/MD Anderson Strategic Alliance (to AJZ); and by the National Institutes of Health through the Dana-Farber–Harvard Cancer Center Kidney Cancer SPORE grant, P50 CA101942, Damon-Runyon Clinical Investigator Award to JVH (CI-24-04) and MD Anderson{\textquoteright}s Cancer Center Support Grant, CA016672. AJZ was partially supported by the Center for Clinical and Translational Sciences, which is funded by the National Institutes of Health Clinical and Translational Award KL2 RR0224149 from the National Center for Research Resource.",

year = "2011",

month = jun,

day = "28",

doi = "10.1038/bjc.2011.186",

language = "English (US)",

volume = "105",

pages = "112--117",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

AU - Bhatt, R. S.

AU - Zurita, A. J.

AU - O'Neill, A.

AU - Norden-Zfoni, A.

AU - Zhang, L.

AU - Wu, H. K.

AU - Wen, P. Y.

AU - George, D.

AU - Sukhatme, V. P.

AU - Atkins, M. B.

AU - Heymach, J. V.

N1 - Funding Information: This work was supported in part by the Clinical Investigator Training Program, Beth Israel Deaconess Medical Center – Harvard/MIT Health Sciences and Technology (to RSB); by the AstraZeneca/MD Anderson Strategic Alliance (to AJZ); and by the National Institutes of Health through the Dana-Farber–Harvard Cancer Center Kidney Cancer SPORE grant, P50 CA101942, Damon-Runyon Clinical Investigator Award to JVH (CI-24-04) and MD Anderson’s Cancer Center Support Grant, CA016672. AJZ was partially supported by the Center for Clinical and Translational Sciences, which is funded by the National Institutes of Health Clinical and Translational Award KL2 RR0224149 from the National Center for Research Resource.

PY - 2011/6/28

Y1 - 2011/6/28

N2 - Background:Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC.Methods:We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial progenitors (CEPs).Results:In patients with VHL disease and RCC and those with sporadic RCC (N10), CEPs and the CEP:mCEC ratio were higher than in normal subjects (N17) (median CEPs: 0.97 vs 0.19 cells l 1, respectively, P0.01; median CEP:mCEC: 0.92 vs 0.58, respectively, P0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy RCC patient samples (N20), CEPs decreased after surgery (median difference 0.02 cells l 1, 0.06 to 1.2; P0.05).Conclusion: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL.

AB - Background:Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC.Methods:We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial progenitors (CEPs).Results:In patients with VHL disease and RCC and those with sporadic RCC (N10), CEPs and the CEP:mCEC ratio were higher than in normal subjects (N17) (median CEPs: 0.97 vs 0.19 cells l 1, respectively, P0.01; median CEP:mCEC: 0.92 vs 0.58, respectively, P0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy RCC patient samples (N20), CEPs decreased after surgery (median difference 0.02 cells l 1, 0.06 to 1.2; P0.05).Conclusion: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL.

KW - angiogenesis

KW - biomarker

KW - circulating endothelial cells

KW - renal cancer

KW - von Hippel-Lindau (VHL) disease

UR - http://www.scopus.com/inward/record.url?scp=79959737234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959737234&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.186

DO - 10.1038/bjc.2011.186

M3 - Article

C2 - 21673679

AN - SCOPUS:79959737234

SN - 0007-0920

VL - 105

SP - 112

EP - 117

JO - British journal of cancer

JF - British journal of cancer

IS - 1

ER -

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this